Analyst Sees 130% Upside as Viridian Hits $43 Target Post-Lumvoa Approval
VRDN•Viridian Therapeutics secured FDA approval for Lumvoa to treat Thyroid Eye Disease, transitioning into a commercial-stage company and setting up direct competition with Amgen's Tepezza. Wedbush analyst Laura Chico raised the price target to $43, implying 130% upside from its prior ~$18.66 share price.
1. FDA Approval of Lumvoa
The FDA approved Lumvoa for Thyroid Eye Disease, granting Viridian the first commercial-stage therapy in its pipeline and enabling immediate market entry in the rare autoimmune eye disorder segment.
2. Price Target Increase
Wedbush analyst Laura Chico raised the price target to $43 from about $18.66, implying approximately 130% upside, reflecting confidence in Lumvoa’s commercial potential and Viridian’s transition to revenue generation.
3. Competitive Landscape
Lumvoa’s approval positions Viridian to compete directly with Amgen’s Tepezza, intensifying rivalry in the Thyroid Eye Disease market and offering patients an alternative therapeutic option.
4. Commercial Launch Planning
Management outlined next steps for Lumvoa’s launch, including manufacturing scale-up, distribution partnerships and marketing strategy development to support initial commercial shipments and physician outreach.
